Author

S. L. Weinrich

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Acker· 1 shared A. Do· 1 shared A. N. Hata· 1 shared A. Shiba-Ishii· 1 shared B. Y. Yeap· 1 shared D. Ciznadija· 1 shared E. Gross· 1 shared F. Haderk· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Acker

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Structural and functional analysis of lorlatinib analogs reveals roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

A. Shiba-Ishii, T. W. Johnson, I. Dagogo-Jack, M. Mino-Kenudson, T. R. Johnson, P. Wei, S. L. Weinrich, M. A. McTigue, M. A. Walcott, L. Nguyen-Phuong, K. Dionne, A. Acker, L. Kiedrowski, A. Do, J. L. Peterson, , A. N. Hata

This study identifies lorlatinib-resistant ALK mutations and evaluates analogs to develop targeted therapies for compound resistance in ALK-positive lung cancer.

Nature Cancer · Jun 20, 2022Peer-reviewedCancer Biology

A tyrosine kinase protein interaction map reveals targetable EGFR network oncogenesis in lung cancer

S. Kaushik, F. Haderk, X. Zhao, H.-M. Hu, K. N. Shah, G. M. Jang, V. Olivas, S. Nanjo, V. B. Masto, D. Ciznadija, I. Sloma, E. Gross, S. L. Weinrich, J. R. Johnson, T. G. Bivona, , S. Bandyopadhyay

The paper constructs a tyrosine kinase protein interaction map, revealing EGFR network oncogenesis in 19% of EGFR wild-type lung cancers, which is targetable with EGFR inhibitors.

bioRxiv · Jul 2, 2020 · PreprintCancer Biology